(Washington, DC) — The use of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) is significantly associated with lower levels of prostate-specific antigen (PSA).
Hemodilution from increased circulating plasma volumes could explain why obese men with prostate cancer have lower serum PSA levels than non-obese men with the malignancy, according to researchers. A ...
Medscape: AACR FCPR 2008: NSAIDs Lower PSA, But May Not Reduce Prostate Cancer Risk
AACR FCPR 2008: NSAIDs Lower PSA, But May Not Reduce Prostate Cancer Risk
Among men with PSA persistence after radical prostatectomy, a higher preoperative PSA surprisingly was linked to lower mortality. Men with PSA persistence and preoperative PSA >20 ng/mL had 31% lower ...
NorthJersey.com: Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Significantly Reduces PSA Levels in Human Prostate Cancer Cells
Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Significantly Reduces PSA Levels in Human Prostate Cancer Cells
NEW YORK (Reuters Health) - On average, men's levels of prostate-specific antigen (PSA) decrease as their body mass index (BMI) rises, a new study shows. PSA is a marker for prostate cancer risk when ...
Renal & Urology News: Lower PSA Linked to Greater Plasma Volume in Obese PCa Patients
Renal & Urology News: Low Baseline PSA Levels at Midlife Tied With Low Prostate Cancer Risk Over 20 Years
Low Baseline PSA Levels at Midlife Tied With Low Prostate Cancer Risk Over 20 Years
ascopubs.org: Association of early achievement of ultra-low PSA levels with radiologic progression-free survival (rPFS) in metastatic hormone-sensitive prostate cancer (mHSPC).
Association of early achievement of ultra-low PSA levels with radiologic progression-free survival (rPFS) in metastatic hormone-sensitive prostate cancer (mHSPC).